Health
Biotechnology
Biopharmaceutical

Incyte

$85.34
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$1.74 (-2.00%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Incyte and other stocks, options, ETFs, and crypto commission-free!

About

Incyte Corp. Common Stock, also called Incyte, is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Read More Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.

Employees
1,367
Headquarters
Wilmington, Delaware
Founded
1991
Market Cap
18.57B
Price-Earnings Ratio
167.33
Dividend Yield
0.00
Average Volume
1.82M
High Today
$87.09
Low Today
$85.30
Open Price
$86.75
Volume
488.45K
52 Week High
$88.83
52 Week Low
$57.00

Collections

Health
Biotechnology
Biopharmaceutical
Pharmaceutical
Technology
Therapy

Earnings

-$0.43
-$0.13
$0.17
$0.47
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected Apr 30, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.